The acquisition adds a differentiated, FDA-cleared product to Axogen's portfolio with immediate revenue contribution. Watch for Q4 2026 earnings to see if the ~$6M BioCircuit contribution materializes and whether Axogen raises its 2027 revenue guidance above the implied ~$34M run-rate.
Price Chart
Executive Summary
Axogen completed its acquisition of BioCircuit Technologies, adding the FDA-cleared NerveTape sutureless nerve repair device. The company expects BioCircuit to contribute ~$6M to Q4 2026 revenue and ~$34M to 2027 revenue, incremental to its prior 2026 guidance of at least 24% revenue growth. Axogen also reaffirmed its 2026 gross margin target of at least 73% and free cash flow positivity.
Key Facts
- Acquisition of BioCircuit Technologies closed on October 1, 2026
- NerveTape is the first FDA-cleared sutureless device for peripheral nerve repair
- Expected Q4 2026 revenue contribution from BioCircuit: ~$6 million
- Expected 2027 revenue contribution from BioCircuit: ~$34 million
- BioCircuit contribution was not included in Axogen's prior FY2026 guidance of at least 24% revenue growth
- Axogen continues to expect FY2026 gross margin of at least 73%
- Axogen continues to expect to be free cash flow positive for FY2026
Financial Impact
~$6M incremental Q4 2026 revenue and ~$34M incremental 2027 revenue from BioCircuit; prior FY2026 guidance of at least 24% revenue growth unchanged but now supplemented by acquisition
Risk Factors
- Integration risk — BioCircuit's revenue contribution may not materialize as forecast
- NerveTape adoption may be slower than expected if surgeons prefer microsuturing
- Acquisition price and deal structure were not disclosed, leaving potential dilution or debt unknown
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000805928-26-000104 |
| Exhibit: ex991axgnpressreleasedated.htm | 0000805928-26-000104 |
| Document: 0000805928-26-000104-index-headers.html | 0000805928-26-000104 |
| Document: 0000805928-26-000104-index.html | 0000805928-26-000104 |
| Document: 0000805928-26-000104.txt | 0000805928-26-000104 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | SC 13G | $37.22 $37.11 | ▼ −0.30% | ▼ −0.72% | $38.01 (+2.11%) |
Oct 1, 2026 25d ago | 8-K | $37.39 $36.13 | ▼ −3.37% | ▼ −4.53% | $38.01 (+1.64%) |
Oct 1, 2026 25d ago | Press Release | $37.39 $36.13 | ▼ −3.37% | ▼ −4.53% | $38.01 (+1.64%) |
Sep 10, 2026 6w ago | 424B5 | $42.16 $44.23 | ▲ +4.91% | ▲ +5.13% | $38.01 (−9.86%) |
Sep 10, 2026 6w ago | 8-K | $41.85 $45.29 | ▲ +8.21% | ▲ +8.71% | $38.01 (−9.19%) |
Sep 10, 2026 6w ago | Press Release | $41.85 $45.29 | ▼ −8.21% | ▼ −8.71% | $38.01 (+9.19%) |
Sep 10, 2026 6w ago | Press Release | $41.85 $45.29 | ▲ +8.21% | ▲ +8.71% | $38.01 (−9.19%) |
Aug 12, 2026 10w ago | Insider Cluster | $48.05 $46.44 | ▼ −3.35% | ▼ −1.39% | $38.01 (−20.91%) |
Aug 11, 2026 10w ago | Institutional Cluster | $49.67 $48.93 | ▼ −1.49% | ▼ −1.05% | $38.01 (−23.48%) |
Jul 29, 2026 12w ago | 8-K | $41.37 $45.22 | ▲ +9.31% | ▲ +3.78% | $38.01 (−8.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers